{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:27:34Z","timestamp":1789637254706,"version":"4.0.0"},"reference-count":19,"publisher":"American Diabetes Association","issue":"6","license":[{"start":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T00:00:00Z","timestamp":1589932800000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/www.diabetesjournals.org\/content\/license"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,6,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>To determine the effect of tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptors, on biomarkers of nonalcoholic steatohepatitis (NASH) and fibrosis in patients with type 2 diabetes mellitus (T2DM).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>Patients with T2DM received either once weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo for 26 weeks. Changes from baseline in alanine aminotransferase (ALT), aspartate aminotransferase (AST), keratin-18 (K-18), procollagen III (Pro-C3), and adiponectin were analyzed in a modified intention-to-treat population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Significant (P &amp;lt; 0.05) reductions from baseline in ALT (all groups), AST (all groups except tirzepatide 10 mg), K-18 (tirzepatide 5, 10, 15 mg), and Pro-C3 (tirzepatide 15 mg) were observed at 26 weeks. Decreases with tirzepatide were significant compared with placebo for K-18 (10 mg) and Pro-C3 (15 mg) and with dulaglutide for ALT (10, 15 mg). Adiponectin significantly increased from baseline with tirzepatide compared with placebo (10, 15 mg).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>In post hoc analyses, higher tirzepatide doses significantly decreased NASH-related biomarkers and increased adiponectin in patients with T2DM.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc19-1892","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T04:16:12Z","timestamp":1586924172000},"page":"1352-1355","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":324,"title":["Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes"],"prefix":"10.2337","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct03131687","registry":"10.18810\/clinical-trials-gov","type":"results"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2396-7356","authenticated-orcid":false,"given":"Mark L.","family":"Hartman","sequence":"first","affiliation":[{"name":"Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun J.","family":"Sanyal","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University, Richmond, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Loomba","sequence":"additional","affiliation":[{"name":"NAFLD Research Center, Department of Medicine, University of California, San Diego, La Jolla, CA"},{"name":"Division of Gastroenterology, Department of Medicine, University of California, San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Wilson","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Nikooienejad","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Bray","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrisanthi A.","family":"Karanikas","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Duffin","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9694-7319","authenticated-orcid":false,"given":"Deborah A.","family":"Robins","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Haupt","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2020,4,14]]},"reference":[{"key":"2022031300321640900_B1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"2022031300321640900_B2","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1111\/dom.12973","article-title":"Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes","volume":"19","author":"Cusi","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"2022031300321640900_B3","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"2022031300321640900_B4","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"key":"2022031300321640900_B5","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/hep.25772","article-title":"Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis","volume":"56","author":"Loomba","year":"2012","journal-title":"Hepatology"},{"key":"2022031300321640900_B6","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Romero-G\u00f3mez","year":"2017","journal-title":"J Hepatol"},{"key":"2022031300321640900_B7","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"2022031300321640900_B8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol Metab"},{"key":"2022031300321640900_B9","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"key":"2022031300321640900_B10","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/hep.22429","article-title":"Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes","volume":"48","author":"Fracanzani","year":"2008","journal-title":"Hepatology"},{"key":"2022031300321640900_B11","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1053\/j.gastro.2010.09.038","article-title":"Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study","volume":"140","author":"Williams","year":"2011","journal-title":"Gastroenterology"},{"key":"2022031300321640900_B12","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1210\/jc.2015-1966","article-title":"High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels","volume":"100","author":"Portillo-Sanchez","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031300321640900_B13","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/dme.13697","article-title":"Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme","volume":"35","author":"Cusi","year":"2018","journal-title":"Diabet Med"},{"key":"2022031300321640900_B14","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/hepr.12197","article-title":"Serum cytokeratin-18 in the diagnosis of non-alcoholic steatohepatitis: a meta-analysis","volume":"44","author":"Chen","year":"2014","journal-title":"Hepatol Res"},{"key":"2022031300321640900_B15","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1016\/j.cgh.2014.05.010","article-title":"Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease","volume":"12","author":"Vuppalanchi","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022031300321640900_B16","doi-asserted-by":"crossref","first-page":"12414","DOI":"10.1038\/s41598-018-30457-y","article-title":"An evaluation of the collagen fragments related to fibrogenesis and fibrolysis in nonalcoholic steatohepatitis","volume":"8","author":"Luo","year":"2018","journal-title":"Sci Rep"},{"key":"2022031300321640900_B17","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.2337\/dc18-2578","article-title":"Use of plasma fragments of propeptides of type III, V, and VI procollagen for the detection of liver fibrosis in type 2 diabetes","volume":"42","author":"Bril","year":"2019","journal-title":"Diabetes Care"},{"key":"2022031300321640900_B18","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/j.1478-3231.2009.02022.x","article-title":"Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease","volume":"29","author":"Lemoine","year":"2009","journal-title":"Liver Int"},{"key":"2022031300321640900_B19","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1038\/oby.2009.219","article-title":"Differential effect of weight loss on adipocyte size subfractions in patients with type 2 diabetes","volume":"17","author":"Pasarica","year":"2009","journal-title":"Obesity (Silver Spring)"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/care.diabetesjournals.org\/syndication\/doi\/10.2337\/dc19-1892","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/43\/6\/1352\/630328\/dc191892.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/43\/6\/1352\/630328\/dc191892.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T03:49:35Z","timestamp":1647143375000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/43\/6\/1352\/35649\/Effects-of-Novel-Dual-GIP-and-GLP-1-Receptor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,14]]},"references-count":19,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,4,14]]},"published-print":{"date-parts":[[2020,6,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc19-1892","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,14]]}}}